array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2445) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(77) "Lonza to Buy Genentech's Vacaville, CA Biologics Manufacturing Site for $1.2B" ["snippet_en"]=> string(141) "Lonza has acquired Genentech’s large-scale biologics manufacturing site in Vacaville, CA, from Genentech’s parent Roche for $1.2 billion." ["url"]=> string(123) "https://www.genengnews.com/topics/bioprocessing/lonza-to-buy-genentechs-vacaville-ca-biologics-manufacturing-site-for-1-2b/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bf63effa-094c-4c54-b086-8401fc264cff" ["source"]=> string(14) "genengnews.com" ["publication_date"]=> string(10) "2024-03-22" ["categories"]=> array(3) { [0]=> string(14) "Product Launch" [1]=> string(11) "Acquisition" [2]=> string(8) "Epidemic" } } [1]=> array(7) { ["title_en"]=> string(61) "2seventy bio to sell experimental cell therapies to Regeneron" ["snippet_en"]=> string(255) "(Reuters) -Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the two companies said on Tuesday. 2seventy bi..." ["url"]=> string(90) "https://whbl.com/2024/01/30/2seventy-bio-to-sell-experimental-cell-therapies-to-regeneron/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/194b176b-e89b-4c55-a6ba-2a17ce2670fe" ["source"]=> string(8) "whbl.com" ["publication_date"]=> string(10) "2024-01-30" ["categories"]=> array(1) { [0]=> string(11) "Acquisition" } } [2]=> array(7) { ["title_en"]=> string(55) "Regeneron to acquire 2seventy’s cell therapy pipeline" ["snippet_en"]=> string(155) "About 150 of the smaller company's employees will also transition to Regeneron, which is setting up a new cellular medicines research and development unit." ["url"]=> string(92) "https://www.biopharmadive.com/news/regeneron-2seventy-cell-therapy-pipeline-purchase/705955/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7b5bbe9c-6a35-4db8-89ff-fcbfbdc585e0" ["source"]=> string(17) "biopharmadive.com" ["publication_date"]=> string(10) "2024-01-30" ["categories"]=> array(2) { [0]=> string(5) "R & D" [1]=> string(11) "Acquisition" } } [3]=> array(7) { ["title_en"]=> string(37) "Regeneron Pharmaceuticals takes 1.10%" ["snippet_en"]=> string(85) "Regeneron Pharmaceuticals takes 1.10% By Otto BottOtto Bott By Otto Bott Otto Bott" ["url"]=> string(97) "https://www.boursier.com/actions/actualites/news/regeneron-pharmaceuticals-prend-1-10-898265.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dafe3536-b1d5-4cc5-b040-44cab8fc36dc" ["source"]=> string(12) "boursier.com" ["publication_date"]=> string(10) "2024-01-16" ["categories"]=> array(1) { [0]=> string(11) "Acquisition" } } [4]=> array(7) { ["title_en"]=> string(48) "Wall Street Comments on Uber, Lyft and Regeneron" ["snippet_en"]=> string(167) "Nomura downgraded Uber (NYSE:UBER) shares to neutral buy, raising their target price to $62 from $59, DKNews.kz reports. The firm believes the company's shares are now" ["url"]=> string(85) "https://dknews.kz/ru/biznes/312002-kommentarii-na-uoll-strit-po-uber-lyft-i-regeneron" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c73af0e3-5210-440f-8b55-8705c2a06d9a" ["source"]=> string(9) "dknews.kz" ["publication_date"]=> string(10) "2024-01-01" ["categories"]=> array(9) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(21) "Intellectual Property" [2]=> string(8) "Verdicts" [3]=> string(18) "General Investment" [4]=> string(5) "Legal" [5]=> string(21) "Competitive Behaviour" [6]=> string(46) "Management of Legal and Regulatory Environment" [7]=> string(11) "Acquisition" [8]=> string(12) "Stock Market" } } [5]=> array(7) { ["title_en"]=> string(49) "Regeneron Buys Avon R&D Facility for $3.9 Million" ["snippet_en"]=> string(220) "Regeneron, the global biotechnology company headquartered in Tarrytown, has purchased an Avon research and development center in the Village of Suffern for nearly $3.9 million, according to Rockland County records. [...]" ["url"]=> string(94) "https://riverjournalonline.com/business/regeneron-buys-avon-rd-facility-for-3-9-million/91198/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5d263b97-a61b-44fd-b5d9-3dd97c4c1cf9" ["source"]=> string(22) "riverjournalonline.com" ["publication_date"]=> string(10) "2023-12-28" ["categories"]=> array(3) { [0]=> string(20) "Business Development" [1]=> string(18) "Expansion & Growth" [2]=> string(11) "Acquisition" } } [6]=> array(7) { ["title_en"]=> string(72) "Commit To Buy Regeneron Pharmaceuticals At $470, Earn 2.7% Using Options" ["snippet_en"]=> string(277) "Investors considering a purchase of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) stock, but tentative about paying the going market price of $832.12/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put con" ["url"]=> string(102) "https://www.nasdaq.com/articles/commit-to-buy-regeneron-pharmaceuticals-at-$470-earn-2.7-using-options" ["image_url"]=> NULL ["source"]=> string(10) "nasdaq.com" ["publication_date"]=> string(10) "2023-10-11" ["categories"]=> array(6) { [0]=> string(11) "Competition" [1]=> string(18) "General Investment" [2]=> string(15) "Market Movement" [3]=> string(9) "Investors" [4]=> string(11) "Acquisition" [5]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(112) "Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss" ["snippet_en"]=> string(262) "TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs." ["url"]=> string(98) "https://finance.yahoo.com/news/regeneron-completes-acquisition-decibel-therapeutics-123400692.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/99c34ab2-0d78-4951-851f-d749a3d5dbb2" ["source"]=> string(9) "yahoo.com" ["publication_date"]=> string(10) "2023-09-25" ["categories"]=> array(1) { [0]=> string(11) "Acquisition" } } [8]=> array(7) { ["title_en"]=> string(170) "More US States Take on Eli Lilly in Court Over Proposed Insulin Pricing Settlement + Regeneron's High Dose Eylea Wins FDA Approval – Xtalks Life Science Podcast Ep. 125" ["snippet_en"]=> string(295) "In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin" ["url"]=> string(182) "https://xtalks.com/more-us-states-take-on-eli-lilly-in-court-over-proposed-insulin-pricing-settlement-regenerons-high-dose-eylea-wins-fda-approval-xtalks-life-science-podcast-ep-125/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/b8e7799f-62e6-42e8-904b-e0e36483d2c3" ["source"]=> string(10) "xtalks.com" ["publication_date"]=> string(10) "2023-08-30" ["categories"]=> array(4) { [0]=> string(5) "Legal" [1]=> string(10) "Litigation" [2]=> string(11) "Acquisition" [3]=> string(16) "Case Settlements" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(197) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(193) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(152) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(101) } [4]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(95) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(83) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(70) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(61) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(51) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(50) } [10]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(46) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(44) } [12]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(35) } [14]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [15]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [16]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(33) } [17]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(32) } [18]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [19]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(30) } [22]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(29) } [23]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(20) } [29]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc